EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Continuing or stopping 5‐aminosalicylates in patients with inflammatory bowel disease on anti‐ TNF therapy: A nationwide population‐based study

Jeongkuk Seo iD, Seonok Kim, Seung Wook Hong, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Jeong-Sik Byeon iD, Seung-Jae Myung, Suk-Kyun Yang iD, Ye-Jee Kim, Byong Duk Ye iD

Alimentary Pharmacology & Therapeutics · 2024-08 · 60 (3) · 389-400

DOI: 10.1111/apt.18102 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 12.06.2024. Verfasst von Jeongkuk Seo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. Hauptthemen laut MEDLINE: Mesalamine. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The impact of continuing or stopping 5‐aminosalicylates (5‐ASA) after commencing anti‐tumour necrosis factor (anti‐TNF) therapy in patients with inflammatory bowel disease (IBD) remains unclear.

Aims

To compare the outcomes of patients with IBD who stopped or continued 5‐ASA after starting anti‐TNF therapy.

Methods

We analysed data from the Korean National Health Insurance claims database between 2007 and 2020. We compared the clinical outcomes of patients who stopped or continued 5‐ASA within 90 days of anti‐TNF initiation. The primary outcome was any adverse clinical event defined as a composite of new corticosteroid use, IBD‐related hospitalisation, or intestinal surgery.

Results

Among 7442 patients included for analysis (4479 [60.2%] with Crohn's disease [CD] and 2963 [39.8%] with ulcerative colitis [UC]), 1037 (13.9%) discontinued 5‐ASA within 90 days of starting anti‐TNF therapy. During a median 4.3‐year follow‐up, discontinuation of 5‐ASA was not associated with an increased risk of adverse clinical events (adjusted hazard ratio 1.01, 95% confidence interval 0.93–1.10). The cumulative incidence of each adverse clinical event and the composite outcome were not significantly different between groups (all, p > 0.05). Additionally, separate analyses in CD and UC cohorts revealed no differences in adverse clinical outcomes between the 5‐ASA continuation and discontinuation groups. Subgroup analyses by presumed risk factors for disease relapse showed no significant differences in the risk of adverse events between groups.

Conclusions

In this nationwide population‐based study, discontinuing 5‐ASA after starting anti‐TNF therapy was not associated with an increased risk of adverse events in patients with IBD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MesalamineHumansFemaleMaleAdultMiddle AgedRepublic of KoreaCrohn DiseaseInflammatory Bowel DiseasesTumor Necrosis Factor-alphaAnti-Inflammatory Agents, Non-SteroidalColitis, UlcerativeYoung AdultAgedRetrospective Studies

Substanzen

MesalamineTumor Necrosis Factor-alphaAnti-Inflammatory Agents, Non-Steroidal

Autor:innen und Institutionen

  • Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
  • Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Digestive Diseases Research Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Inflammatory Bowel Disease Center, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.

ORCID-Profile: Jeongkuk Seo, Jeong-Sik Byeon, Suk-Kyun Yang, Byong Duk Ye

Förderung

  • National Research Foundation of Korea

Zitieren

APA

Seo, J., Kim, S., Hong, S. W., Hwang, S. W., Park, S. H., Yang, D. H., Byeon, J. S., Myung, S. J., Yang, S. K., Kim, Y. J., & Ye, B. D. (2024). Continuing or stopping 5‐aminosalicylates in patients with inflammatory bowel disease on anti‐ TNF therapy: A nationwide population‐based study. Alimentary Pharmacology & Therapeutics, 60(3), 389-400. https://doi.org/10.1111/apt.18102

Vancouver

Seo J, Kim S, Hong SW, Hwang SW, Park SH, Yang DH, et al. Continuing or stopping 5‐aminosalicylates in patients with inflammatory bowel disease on anti‐ TNF therapy: A nationwide population‐based study. Alimentary Pharmacology & Therapeutics. 2024;60(3):389-400. doi:10.1111/apt.18102

BibTeX
@article{Seo2024,
  author = {Seo, Jeongkuk and Kim, Seonok and Hong, Seung Wook and Hwang, Sung Wook and Park, Sang Hyoung and Yang, Dong-Hoon and Byeon, Jeong-Sik and Myung, Seung-Jae and Yang, Suk-Kyun and Kim, Ye-Jee and Ye, Byong Duk},
  title = {Continuing or stopping 5‐aminosalicylates in patients with inflammatory bowel disease on anti‐ TNF therapy: A nationwide population‐based study},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  volume = {60},
  number = {3},
  pages = {389--400},
  doi = {10.1111/apt.18102}
}
Kostenlos starten →